Abstract
Thirty-six HIV-infected patients with chronic hepatitis C treated with peginterferon alpha-2a or 2b plus ribavirin were analysed in a prospective observational study. The were 15 (42%) treatment discontinuations; bt intent-to-treat virological responders were 19 (53%) at week 24. A higher fibrosis score predicted premature discontinuation of hepatitis C virus (HCV) therapy and a lack of early virological response. Female sex and HCV genotype predicted early virological responses. Results support the early treatment of HCV in co-infected individuals.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antiviral Agents / therapeutic use*
-
Cohort Studies
-
Drug Therapy, Combination
-
Female
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
Hepatitis C, Chronic / complications
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use*
-
Liver Cirrhosis / etiology*
-
Male
-
Middle Aged
-
Polyethylene Glycols / therapeutic use*
-
Prospective Studies
-
Recombinant Proteins
-
Ribavirin / therapeutic use*
-
Treatment Outcome
Substances
-
Antiviral Agents
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
peginterferon alfa-2a